greeksoup/ stocks
Stocks / United States / MRK / Q1 FY2026

Merck & Co., Inc. Q1 FY2026 results: revenue $16.3 billion, up 4.9% on the year

Merck & Co., Inc. (MRK) reported revenue of $16.3 billion for Q1 FY2026, the quarter ended 31 March 2026, up 4.9% on the same quarter a year earlier. Net income was -$4.2 billion, and diluted earnings per share $-1.72. The figures are the company's own, from the 10-Q it filed with the SEC on 4 May 2026.

Revenue$16.3 billionup 4.9%
Net income-$4.2 billion
Diluted EPS$-1.72
QuarterQ1 FY2026ended 31 March 2026

The quarter, against the one before and a year earlier

LineQ1 FY2026Q4 FY2025Q1 FY2025Change on the year
Revenue16,28616,40015,529+4.9%
Cost of revenue4,1955,5513,419+22.7%
Gross profit12,09110,84912,110-0.2%
Gross margin74.2%66.2%78.0%
Research and development12,5923,8863,621+247.7%
Selling, general and administrative2,7002,8992,552+5.8%
Interest expense479412313+53.0%
Pre-tax income-3,5343,4205,903n/a
Income tax709457818-13.3%
Effective tax raten/a13.4%13.9%
Net income-4,2402,9635,079n/a
Net margin-26.0%18.1%32.7%
Diluted EPS-$1.72$1.19$2.01n/a

$ million except per share. Fourth quarters are the year less the first three quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow and capital returned

LineQ1 FY2026Q4 FY2025Q1 FY2025Change on the year
Operating cash flow3,9182,8572,500+56.7%
Capital expenditure9911,0331,328-25.4%
Free cash flow2,9271,8241,172+149.7%
Free cash flow margin18.0%11.1%7.5%
Share-based compensation185205195-5.1%
Buybacks8741,2521,164-24.9%
Dividends paid2,1052,0182,050+2.7%
Dividend per share$0.85n/a$0.81+4.9%
Diluted shares, weighted2,472m2,507m2,531m-2.3%
Shares outstanding at period end2,470m2,472m2,511m-1.6%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet at quarter end

LineQ1 FY2026Q4 FY2025Q1 FY2025Change on the year
Total assets128,685136,866115,122+11.8%
Cash and equivalents5,32714,5658,629-38.3%
Receivables12,21011,77510,790+13.2%
Inventory6,4796,6586,196+4.6%
Goodwill21,58121,57921,684-0.5%
Total debt, as filed49,10049,30034,800+41.1%
Long-term debt46,67346,75033,484+39.4%
Operating lease liabilitiesn/a901n/an/a
Shareholders' equity45,87852,60648,335-5.1%

Quarterly results, the last 12 quarters

Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026
Revenue15,96214,63115,77516,11216,65715,62415,52915,80617,27616,40016,28616,607
Cost of revenue4,2643,9123,5403,7454,0803,8283,4193,5573,8555,5514,1954,395
Gross profit11,69810,71912,23512,36712,57711,79612,11012,24913,42110,84912,09112,212
Gross margin73%73%78%77%76%75%78%77%78%66%74%74%
R&D3,3079,6273,9923,5005,8624,5843,6214,0484,2343,88612,5929,741
SG&A2,5192,8042,4832,7392,7312,8632,5522,6492,6332,8992,7002,904
Interest expense317310303310330328313305327412479525
Pre-tax income5,620-2,0465,6706,0064,0904,1705,9034,9996,7453,420-3,534-683
Tax rate15%n/a16%9%23%10%14%11%14%13%n/an/a
Net income4,745-1,2264,7625,4553,1573,7435,0794,4275,7852,963-4,240-1,335
Net margin30%-8%30%34%19%24%33%28%33%18%-26%-8%
Diluted EPS$1.86-$0.48$1.87$2.14$1.24$1.49$2.01$1.76$2.32$1.19-$1.72-$0.54
Operating cash flow7,7172463,0905,6379,2913,4502,5003,2937,8222,8573,9185,370
Capital expenditure9029898617917839371,3287649871,033991893
Free cash flow6,815-7432,2294,8468,5082,5131,1722,5296,8351,8242,9274,477
Buybacks4663931222514444891,1641,3451,3231,252874757
Dividends paid1,8551,8521,9501,9861,9531,9512,0502,0772,0312,0182,1052,144
Shares outstanding2,534m2,533m2,533m2,535m2,530m2,526m2,511m2,498m2,482m2,472m2,470m2,467m
Filing10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q

* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Source

10-Q for the period ended 31 March 2026, filed 4 May 2026, accession 0001628280-26-029802: the filing on EDGAR. All of Merck & Co., Inc.'s filings: EDGAR company page.

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install